3 results about "Biological agent" patented technology

A process of preparing a bioformulation includes the stages of preparing air conditions having least contamination for the making of the bioformulation; preparing the bioformulation in the enclosure while maintaining air conditions having least contamination; and initiating enrichment of the bioformulation using cloths. Further is described a method of preparing working solutions from the stock solution of the bioformulation. The working solution of bioformulation is used for treating waste water, polluted soil, polluted air, solid wastes, etc. The process is sustainable and ecofriendly. The process utilizes raw materials that are easily available. The bioformulation of the present invention is useful for bioremediation.

A system for treaty-governed genomic compilation and secure biological synthesis that regulates the translation of digital genetic information into physical matter. The apparatus comprises a Symbolic Verification Kernel configured to deconstruct target nucleic acid sequences into functional semantic representations and execute predictive biological simulations to assess toxicity and dual-use risk against an immutable Treaty Ledger. Physical synthesis is controlled by a hardware-locked DNA synthesis apparatus that remains mechanically disabled until it receives and validates a cryptographically signed Sovereign Synthesis Token issued by the kernel. The system further includes a Bio-Encryption Engine that interleaves non-coding watermarks into the synthesized material, establishing a permanent, molecular-level chain of custody for all fabricated genetic content. The architecture thereby enforces international biological safety constraints directly at the point of manufacture, preventing the unauthorized synthesis of pathogenic or restricted biological agents.

The application discloses a gene modified non-toxic toxoid vaccine based on light chain-transmembrane region L-HN and receptor binding region Hc, and a preparation method and application thereof. The gene modified non-toxic novel toxoid vaccine molecule has two important protective antigen functional domains of a biological toxin, the N terminal of the vaccine molecule is the light chain-transmembrane region L-HN, and the C terminal is the receptor binding region Hc. The two protective antigen functional domains can be derived from the same biological toxin, can produce stronger protection than a single antigen, can produce strong complete protection at a low dose and a small number of immunization times, and can be used as a high-efficiency gene engineering toxoid vaccine to replace formaldehyde inactivated toxoid for biological toxin prevention. The two protective antigen functional domains can also be derived from different biological toxins, can protect against attacks of respective biological toxins, can produce protection against multiple different toxin biological agents, and can be used as a broad-spectrum multivalent vaccine for biological toxin prevention.